By Denny Jacob
Genelux named Matthew Pulisic as chief financial officer.
The late clinical-stage immuno-oncology granted the new executive a base salary of $410,000 and made him eligible for an annual discretionary bonus with a target amount of up to 40% of his then-current base salary based on certain achievements. Pulisic has also been granted an option to purchase 275,000 shares of common stock of the company with a per-share exercise price of $3.95 a share.
Pulisic most recently served as vice president of finance at Arrowhead Pharmaceuticals, an RNAi technology company.
Genelux's change at CFO comes as Lourie Zak resigned days earlier. She and the company entered into a separation agreement in which she will serve as a non-employee advisor that will conclude on Aug. 29 unless earlier terminated, among other terms.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
February 03, 2025 06:58 ET (11:58 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。